X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Vibegron
Therapeutic Area: Gastroenterology Product Name: Gemtesa
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
Vibegron was very well tolerated in the study and did not lead to any worsening of IBS symptoms. Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Surveyor Capital
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 15, 2020
Details:
Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBT-401
Therapeutic Area: Gastroenterology Product Name: BBT-401
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bridge Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 15, 2020
Details:
BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
